JIANGSU

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Retrieved on: 
Thursday, January 5, 2023
Conference, SAN, Biotechnology, Pharmaceutical industry, Property insurance

SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference.
  • Details of the event are as follows:

Ostin Technology Group to Attend Consumer Electronics Show 2023 in Las Vegas with Independently Developed Products - Updated

Retrieved on: 
Wednesday, January 4, 2023
Tao, CES, Electronics, Mo Ostin, Methodist Central Hall, Westminster, Consumer electronics, Align Technology, Central Hall, LVCC, Advertising, Intelligence, Video game

NANJING, China, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it will attend the Consumer Electronics Show 2023 (the “CES”) to be held from January 5 to 8, 2023 in Las Vegas, United States.

Key Points: 
  • NANJING, China, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it will attend the Consumer Electronics Show 2023 (the “CES”) to be held from January 5 to 8, 2023 in Las Vegas, United States.
  • The Company will showcase its portable panel and all-in-one PC products, and the two independently developed new products - Pintura photo-sharing and video conference products at the global trade show.
  • CES is a major event in the technology industry, featuring breakthrough technologies and innovative companies from around the world, including manufacturers, developers, and suppliers of consumer technology hardware, content, and delivery systems.
  • It is independently developed by the Company and has two components: conferencing system and conference room scheduling panel.

Ostin Technology Group to Attend Consumer Electronics Show 2023 in Las Vegas with Independently Developed Products

Retrieved on: 
Wednesday, January 4, 2023
Tao, CES, Electronics, Mo Ostin, Methodist Central Hall, Westminster, Consumer electronics, Align Technology, Central Hall, LVCC, Advertising, Intelligence, Video game

NANJING, China, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it will attend the Consumer Electronics Show 2023 (the “CES”) to be held from January 5 to 8, 2023 in Las Vegas, United States.

Key Points: 
  • NANJING, China, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it will attend the Consumer Electronics Show 2023 (the “CES”) to be held from January 5 to 8, 2023 in Las Vegas, United States.
  • The Company will showcase its portable panel and all-in-one PC products, and the two independently developed new products - Pintura photo-sharing and video conference products at the global trade show.
  • CES is a major event in the technology industry, featuring breakthrough technologies and innovative companies from around the world, including manufacturers, developers, and suppliers of consumer technology hardware, content, and delivery systems.
  • It is independently developed by the Company and has two components: conferencing system and conference room scheduling panel.

CGN selects RayStation for Yangzhou Hospital

Retrieved on: 
Wednesday, January 4, 2023
Proton, Photon, Proton therapy, Patient, RaySearch Laboratories, Nasdaq Stockholm, Health, Life, CGN, Karolinska Institute, Carbon, Helium, HDR, Ion, TCS, OIS, OAS, Cancer, IBA, Electron, TPS, Medical imaging, Lithium

STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that CGN Medical Technologies has in December 2002 placed an order for RayStation®*, which CGN has sold together with IBA's proton therapy system to Yangzhou Hospital in China.

Key Points: 
  • STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that CGN Medical Technologies has in December 2002 placed an order for RayStation®*, which CGN has sold together with IBA's proton therapy system to Yangzhou Hospital in China.
  • RayStation has been sold in combination with IBA's proton therapy systems in China before, but the current order is the first one that RaySearch receives from CGN.
  • Today, RayStation is the market leader in this segment of cancer care, a position that is further strengthened by the new order.
  • RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®.

Ostin Technology Group Unveils First Independently-Developed All-In-One Intelligent Video Conference Product and Plans Official Product Launch at Consumer Electronics Show 2023

Retrieved on: 
Friday, December 16, 2022
Tao, PC, Electronics, Facial recognition, Communication, LCD, Marketing, Consumer Electronics Show, MEMS, Noise, Software design, COVID-19, Sound localization, Organization, Research, Wi-Fi, Bluetooth, Mercer (consulting firm), CES, Mobile phone, Video game console, Central Hall

This device is perfect for medium-sized rooms as it supports wireless deployment and is compatible with most cloud platforms.

Key Points: 
  • This device is perfect for medium-sized rooms as it supports wireless deployment and is compatible with most cloud platforms.
  • It can also serve as a smart screen, speaker, camera, as well as PC audio and video peripherals.
  • The conference room scheduling panel offers meeting scheduling solutions that can be tailored to fit clients' plans and budgets.
  • We hope that Ostin’s display solutions can empower every customer with more ways to collaborate.”
    About Ostin Technology Group Co., Ltd.

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

Retrieved on: 
Friday, December 16, 2022
Roche, DPL, Annual report, Computational biology, Intellectual property, Tumor microenvironment, SAN, Liver cancer, Antibody, FDA, Therapeutic index, TME, Safety, Science, Cancer, ADAG, Pharmacokinetics, Intelligence, Malignancy, Hepatocellular carcinoma, Kamangar, Villanueva, Bevacizumab, Death, WHO, COVID-19, Cirrhosis, Patient, Therapy, HCC, Pharmaceutical industry, Vaccine

The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.

Key Points: 
  • The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.
  • Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone, initially in 60 patients.
  • Each company is supplying its respective anti-cancer agent(s) to support the trial.
  • Adagene will retain global development and commercialization rights to ADG126.

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Retrieved on: 
Monday, November 21, 2022
COVID-19, Growth, Ascites, SAN, Science, Dartmouth College, Antibody, DPL, McKinsey & Company, Partnership, Merck, MBA, Patient, Dartmouth, Samsung, Pembrolizumab, Computational biology, ESMO, Annual report, Tuck School of Business, WeChat, Therapeutic index, MSS, SITC, Intellectual property, Intelligence, Entrepreneurship, Business, CRC, Safety, BA, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagenes board of directors (the Board) as an independent director.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagenes board of directors (the Board) as an independent director.
  • He will also serve as an audit committee member.
  • Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimers Disease, Parkinsons disease and refractory Ascites.
  • Im very excited to join the Adagene board and do what I can to help advance our programs to help our patients, commented Mr. Do.

Two foreign-funded projects sign agreements to locate in Changzhou National Hi-Tech District with total investment of US$135 million

Retrieved on: 
Tuesday, November 15, 2022
CND, General manager, R, Research, Multimedia, Renewable energy

Among the 53 projects, two with a total investment of US$135 million chose ChangzhouNationalHi-TechDistrict(CND) as their headquarters, representing new breakthroughs for CND in terms of capturing major projects.

Key Points: 
  • Among the 53 projects, two with a total investment of US$135 million chose ChangzhouNationalHi-TechDistrict(CND) as their headquarters, representing new breakthroughs for CND in terms of capturing major projects.
  • Once the new facility is put into operation, annual output value is expected to reach 300 million yuan (approx.
  • Xu Lida, Chief Financial Officer of the new company said that the group attaches great importance to the Chinese market.
  • After the completion of the new project, a production facility that Lesjfors already has in Shanghai will be incorporated into the Changzhou operation, further facilitating large-scale production.

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, DPL, IO, Combination therapy, Antigen, Head, Intellectual property, DLT, Ipilimumab, Melanoma, Objective, Intelligence, Toxic leukoencephalopathy, Carcinoembryonic antigen, Interim, Annual general meeting, MSS, Immunotherapy, Neoplasm, TTL, Colorectal cancer, Technology, Renal cell carcinoma, HNSCC, Trae tha Truth, Antibody, Patient, Safety, Grade 3, SITC, ADAG, No, U.S. Securities and Exchange Commission, Toxicity, CRC, Computational biology, Science, Pembrolizumab, Liver, DCR, Society, CEA, COVID-19, Pharmaceutical industry, Vaccine

SAN DIEGO and SUZHOU, China, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place in Boston.

Key Points: 
  • Combination data from dose escalation of ADG116 plus the anti-PD-1 therapy, toripalimab, were also reported from nine heavily pre-treated patients, close to half (44%) of whom received three or more lines of prior therapy.
  • Key findings as of the data cutoff date on September 19, 2022 include:
    Compelling, differentiated safety profile demonstrated with ADG116 monotherapy up to 15 mg/kg: ADG116 is well tolerated across dose levels with repeat dosing.
  • Grade 1/2 and Grade 3/4 treatment-related adverse events (TRAEs) were reported in 28 (56%) and 3 (6%) patients, respectively.
  • There were no Grade 3 or higher TRAEs reported at the 15 mg/kg dose level for ADG116 monotherapy.

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

Retrieved on: 
Friday, November 4, 2022
Technology, Company, SM03, Pemphigus, Research, Central China, Therapy, Growth, Asthma, The Company, Non-Hodgkin lymphoma, State Council, NHL, Damage-associated molecular pattern, Lupus, Twelfth, Sino Biopharmaceutical Limited, SLE, Barakat Pharmaceutical Group, RA, Rheumatoid arthritis, The Group, Thirteenth, WANG, CD22, Autoimmune disease, B-cell lymphoma, Mab, Degenerative disease, Pharmaceutical industry, Group

Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.

Key Points: 
  • Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.
  • Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization.
  • Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company.
  • Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares.